About this trial
The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous breast abscess drainage for disinfection of breast abscesses. The study includes two arms: (1) standard of care breast abscess drainage and (2) MB-PDT plus standard of care breast abscess drainage. The primary endpoint is time to resolution of clinical symptoms. Secondary endpoints include imaging evidence of abscess resolution, abscess recurrence, need for repeated intervention, and cure rate across treatment groups. Responses will be compared between the two study arms for the per protocol population to determine the efficacy of MB-PDT relative to standard of care. The investigators hypothesize that the addition of MB-PDT to standard of care will significantly reduce the time to symptom resolution, compared to standard of care alone.
Eligibility criteria
Qualifiers
Adults 18 years or older
Clinical signs of breast abscess, including pain, redness, and/or heat of the breast
Approval by the primary care team to pursue PDT and discuss enrollment with the patient
Disqualifiers
Pregnancy
Lactation
Allergy to contrast media, narcotics, sedatives, atropine or eggs
Necrotic tissue that requires surgical debridement
Trial design
Treatments tested in this trial
- Standard of care breast abscess drainage
- Methylene Blue
- Lipid Emulsion
- Insertion of optical fiber
- Laser illumination
- Photodynamic therapy